Shanghai Synnovis Biopharmaceutical

Synnovis is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, with significant research and development operations in Shanghai. The company focuses on the discovery and development of innovative small molecule and biologic therapies for oncology, metabolic disorders, and inflammatory diseases. Its lead clinical assets include XNW3002, a URAT1 inhibitor in Phase 3 trials for gout, and XNW1011, a next-generation BTK inhibitor for B-cell malignancies. Synnovis utilizes a proprietary structure-based drug design platform to optimize candidates for improved efficacy and safety. The company has successfully raised substantial capital from prominent investors such as Hillhouse Capital and Tencent to advance its diverse pipeline.